The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer. In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first decade after the introduction of the Oncotype DX assay. We found that the use of Oncotype DX has steadily increased in the first decade of use and that this increase is associated with a decreased usage of chemotherapy. Patients who utilized the Oncotype DX test tended to have improved survival compared to patients who did not use the assay even after adjusting for clinical variables associated with prognosis. In addition, chemotherapy usage in patients with high-risk scores is associated with significantly longer overall and breast cancer-specific survival compared to high-risk patients who did not receive chemotherapy. On the contrary, patients with low-risk scores who were treated with chemotherapy tended to have shorter overall survival compared to low-risk patients who forwent chemotherapy. We have provided a comprehensive temporal overview of the use of Oncotype DX in breast cancer patients in the first decade after Oncotype DX was introduced. Our results suggest that the use of Oncotype DX is increasing in ER+ breast cancer and that the Oncotype DX test results provide valuable information for patient treatment and prognosis.

中文翻译：

---

Oncotype DX 测试在使用的头十年对 ER+ 乳腺癌治疗和生存的影响

Oncotype DX 乳房复发评分已于十多年前推出，旨在帮助医生确定早期雌激素受体 (ER)+、淋巴结阴性乳腺癌患者是否需要进行全身辅助化疗。在这项研究中，我们利用来自监测、流行病学和最终结果 (SEER) 计划的数据来调查在引入 Oncotype DX 检测后的第一个十年中美国乳腺癌患者中 Oncotype DX 使用的时间趋势。我们发现 Oncotype DX 的使用量在使用的头十年中稳步增加，并且这种增加与化疗使用量的减少有关。即使在调整与预后相关的临床变量后，使用 Oncotype DX 检测的患者与未使用该检测的患者相比，生存率往往有所提高。此外，与未接受化疗的高危患者相比，高危评分患者的化疗使用与总体生存期和乳腺癌特异性生存期显着延长相关。相反，与放弃化疗的低风险患者相比，接受化疗的低风险评分患者的总生存期往往较短。我们对 Oncotype DX 推出后第一个十年在乳腺癌患者中的使用情况进行了全面的时间概述。我们的结果表明，Oncotype DX 在 ER+ 乳腺癌中的使用正在增加，并且 Oncotype DX 测试结果为患者治疗和预后提供了有价值的信息。